INTRODUCTION
============

Pancreaticoduodenectomy (PD) is the standard treatment recommended for patients with cancer of the head of the pancreas. Historically, Godivilla, an Italian surgeon, and Kausch, a German surgeon, are credited with the introduction of partial pancreaticoduodenectomy in 1898 and 1909, respectively. This procedure was improved by Whipple et al. in 1935. PD entails removal of the head of the pancreas, duodenum, common bile duct, gall bladder, and the distal portion of the stomach together with the adjacent lymph nodes.[@ref1] PD includes both pylorus-resecting pancreaticoduodenectomy (PRPD) and pylorus- preserving pancreaticoduodenectomy (PPPD). PRPD entails resection of pylorus, regardless of the extent of gastric resection. The side effects of PRPD are well known: partial gastric resection is associated with early and late dumping and weight loss after surgery.

PPPD is similar except that the functional pylorus is left at the gastric outlet.[@ref2] It was first reported by Watson[@ref3] in 1944. In the late 1970s, Traverso and Longmire reintroduced PPPD for chronic pancreatitis.[@ref3] PPPD was expected to shorten the operating time but also improve the gastrointestinal function, because the intact gastric mechanism provides better nutrition over a long period of time and an intact pyloric sphincter reduces the incidence of jejunal ulceration and dumping.[@ref1] However, postoperative gastric function is affected adversely after PPPD via delayed gastric emptying (DGE). Gastric emptying mainly depends on intact vagal innervation to the antrum, mainly the nerves of Latarjet and vagus nerve branches.

Several studies suggest that the advantages and disadvantages of PRPD and PPPD depend on postoperative changes after procedure, and not simply on decisions to resect pylorus. The relative effectiveness of the procedures is still disputed. Therefore, the current study was intended to analyze the large clinical data involving PPPD compared with PRPD based on postoperative outcomes, including blood glucose levels, and survival of patients with pancreatic head cancer.

MATERIALS AND METHODS
=====================

Patient database
----------------

This study was retrospectively performed at the Samsung Medical Center to compare PPPD and PRPD in 556 patients with pancreatic head cancer between January 2007 and December 2016. Patients who did not undergo resection after exploration as well as patients who underwent palliative procedures such as gastroenteric bypass surgery were excluded. In this retrospective study, both PPPD and PRPD were not conducted randomly. Pylorus resection is only performed if the patient manifests pylorus invasion or aggressive disease. This study was approved by the institutional review board (Approval number: 2018-05-079) of the Samsung Medical Center. We reviewed the electronic medical records of 556 patients to retrieve clinical, pathological and surgical data. We included patient demographics such as age, body mass index (BMI), underlying diseases such as diabetes, history of cardiovascular disease (coronary heart disease, myocardial infarction, severe carotid stenosis or peripheral arterial occlusive disease), pulmonary disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease), liver disease (e.g., liver cirrhosis, chronic hepatitis B or C), chronic kidney disease, and history of cerebrovascular disease (e.g., stroke, haemorrhage), and American Society of Anaesthesiology (ASA) score.[@ref4] Starting from 2010, we included the criteria associated with revised microscopic resection margin: rR1 (revised grossly negative but microscopically positive resection margin) tumor present within less than 1 mm from surgical margin.[@ref5][@ref6]-[@ref7] Tumor differentiation was graded according to the nomenclature defined by the World Health Organization, and tumor, node, and metastasis (TNM) staging was classified according to the American Joint Committee of Cancer (AJCC) manual, 8th ed.[@ref8] All patients were evaluated preoperatively using computed tomography (CT) with pancreatic protocol and magnetic resonance cholangiography (MRCP). In principle, patients diagnosed with pancreatic head cancer meeting resectable criteria were candidates for preoperative resection. When the patient was diagnosed with borderline resection of pancreatic head cancer, either surgery or neoadjuvant therapy was selectively administered.

Postoperative outcomes included length of hospital stay, major complications defined as Clavien-Dindo grades III to V,[@ref9] and postoperative morbidity and mortality (within 90 days). Pancreatic fistula was defined according to the International Study Group for Pancreatic Fistula (ISGPF) 2016 classification,[@ref10] and DGE according to the ISGPS 2007 definition.[@ref11] In this study, DGE incidence was included from grade A.

All patients received proton pump inhibitor (PPI) prophylaxis against stress ulceration, and octreotide treatment was continued for 7 days. To determine whether the blood glucose level was adjusted after surgery, it was monitored every 6 hours after surgery and followed up until postoperative day 3. After PD, all patients underwent CT scan to evaluate surgical complications, including postoperative pancreatic fistula (POPF), on day 6 or 7 post-surgery. Survival data were obtained from the electronic medical records, and the follow-up period was measured from the time of initial treatment until death or the last follow-up examination. Patient follow-up was completed up to October 2018.

Statistical analysis
--------------------

Categorical variables were presented by number and percentage, and continuous variables were reported as mean, median, and range whenever appropriate. The categorical variables were compared using χ^2^ or linear-by-linear association test, and continuous variables were compared using the Student's *t*-test. Overall survival and comparison of univariable analyses were performed using the Kaplan--Meier method with the log-rank test. *p*\<.05 was considered statistically significant. Multivariable analysis of significant factors yielded results similar to univariable analysis conducted using the Cox proportional hazard model, which was used to calculate the hazard ratio with a 95% confidence interval (CI). All statistical analyses were carried out using IBM SPSS v 25.0 (SPSS, Inc, Chicago, IL).

RESULTS
=======

Among 556 patients with pancreatic head cancer, 318 underwent PPPD and 238 underwent PRPD. Patient demographics are presented in [Table 1](#T1){ref-type="table"}. The proportion of men to women ranged from 54.7% to 45.3% and 67.2% to 32.8% in the PPPD and PRPD groups, respectively. The proportion of sex varied significantly between the two groups (*p*=0.003). There was no significant difference between the two groups for underlying disease except diabetes mellitus (DM). Patients with DM in PPPD were fewer than in PRPD (33.0% vs. 46.2%, *p*=0.002). Among tumor markers, the median value of CA19-9 was significantly higher in PRPD than in PPPD (129.36 vs. 86.47, *p*=0.037). Most intraoperative parameters were not significantly different but intraoperative transfusion in PPPD was less than in PRPD (9.4% vs. 15.5%, *p*=0.028). The number of patients who received neoadjuvant therapy in PPRD was higher than in PPPD (6.3% vs. 2.5%, *p*=0.027).

Pathological findings are presented in [Table 2](#T2){ref-type="table"}. The status of resection margin was significantly different between the two groups: R1 including rR1 in PRPD group was higher than in PPPD (37.8% vs. 29.2%, *p*=0.033).

Postoperative outcomes were shown in [Table 3](#T3){ref-type="table"}. The incidence of major complications defined as Clavien-Dindo grades III to V in PPPD was significantly higher than in PRPD (20.4% vs. 13.4%, *p*=0.032).The major complications are listed in [Table 4](#T4){ref-type="table"}.

As shown in [Table 5](#T5){ref-type="table"}, univariate and multivariate analyses were used to identify risk factors affecting major complications (grade III or higher). Univariate analysis revealed 23 parameters as potential risk factors. Two factors were identified as possible severe complications after pancreaticoduodenectomy: liver disease (*p*=0.005) and ASA score greater than 3 (*p*=0.001). Multivariate logistic regression analysis revealed that two factors were also statistically significant. Resection of pylorus was shown to reduce complications in both univariate and multivariate analyses.

[Fig. 1](#F1){ref-type="fig"} shows the overall survival of PPPD and PRPD. The 5-year survival rates were 27.6% in the PPPD group and 22.4% in the PRPD group (*p*=0.015). There was no significant difference in disease-free survival of recurrence in both groups ([Fig. 2](#F2){ref-type="fig"}).

DISCUSSION
==========

Several studies compared morbidity and mortality of PPPD and PRPD. No significant differences were found in pancreatic fistulas, wound infections, post-operative bleeding, or biliary leakage between PPPD and PRPD.[@ref12] Further, the results of several randomized controlled trials (RCTs) or meta-analyses comparing PPPD and PRPD found that the two procedures were identical with respect to morbidity and mortality associated with the treatment of pancreatic head tumors.[@ref13][@ref14][@ref15][@ref16][@ref17]-[@ref18]

However, a lower rate of DGE was found with PRPD compared with PPPD.[@ref12] According to previous study, several factors play a role in the pathophysiology of DGE. Gastric dysrhythmias, abnormal gastroduodenal nerve connections, ischemia of the pyloric sphincter, and ligation of the right gastric artery are associated with DGE. Resection of the duodenum, the primary production site of most gastrointestinal hormones, might also play a role in the pathogenesis of this complication.[@ref15]

Our study showed that DGE was not significantly different between PRPD and PPPD even though several studies reported that PRPD was superior to PPPD with respect to DGE.[@ref2] This result may be attributed to the small number of DGEs in the patients reviewed in our study compared with the previous studies.

We also showed that postoperative outcomes were not significantly different between PRPD and PPPD except in Clavien-Dindo surgical complications grade ≥3. We evaluated the risk factors for major complications, and showed that systemic disorders with an ASA score more than 3 and liver disease were risk factors for Clavien-Dindo grade ≥3 complications. Similar to our results, previous studies reported that the postoperative outcomes of patients undergoing PD with systemic disorder were poor. Eeson et al.[@ref19] suggested that an ASA score of 3 was associated with a higher 90-day and 5-year mortality rates. Age *per se* should not be considered a contraindication for pancreaticoduodenectomy, but caution is required for patients who are at least 80 years old, especially in the presence of any associated comorbidities resulting in an ASA score of 3.[@ref19] Gouma et al.[@ref20] claimed that serum creatinine levels were independent risk factors for complications. El Nakeeb et al.[@ref21] reported that liver cirrhosis increased the risk of POPF. We found that the patient's ability to endure physiological stress of PD was related to the possibility of postoperative complications.[@ref19]

Our study revealed no differences between the two groups in most of the postoperative outcomes. However, the higher incidence of major complications in PPPD should be attributed to selection bias in this study, rather than pylorus-preserving surgery.

According to PROPP trial, long-term follow-up showed no significant differences between pylorus resection compared with pylorus preservation.[@ref22] Similarly, our study did not show differences in terms of hospitalization and re- hospitalization. In addition, TNM stage and disease-free survival showed no difference between the two groups similar to previous study. However, the overall survival was significantly better in PPPD than in PRPD. In terms of clinicopathologic characteristics, the PRPD group underwent significantly higher CA19-9 and greater R1 resection, which suggested that the PRPD group in our study included patients with advanced cancer. However, the comparison based on TNM stages did not reflect significant differences. In this retrospective study, both PPPD and PRPD were not conducted randomly. Because PPPD is the basic surgical technique recommended for patients with pancreatic head cancer in our institute, pylorus resection is only performed if the patient manifests pylorus invasion or aggressive disease. Therefore, this retrospective survival analysis may not reflect differences in survival between the two procedures.

DM is an independent risk factor associated with complications for pancreatic cancer.[@ref23] A study reported factors contributing to impaired glucose homeostasis and development of DM after pancreatectomy.[@ref23] Factors include age, BMI greater than 23.5 kg/m^2^, family history of DM and resection type.[@ref24] Other studies have shown that pancreatic cancer-related DM improves after tumor resection.[@ref25],[@ref26] The improved glycemic control after PD surgery may be attributed to reduced BMI, altered life style including dietary habits as well as physiological and anatomical changes resulting from gastrointestinal tract reconstruction.[@ref27] The physiological and anatomical changes were attributed to the obesity bypass procedure, which removed duodenal mucosa as a surface of food absorption, and improved blood sugar levels and enhanced weight loss. According to this theory, PRPD is better for the control of blood glucose than PPPD. However, our results did not show statistically significant results.

The study limitations are also worth mentioning. First, our data were collected and analyzed retrospectively. Significant biases may affect the selection of controls. Unlike a meta-analysis, which showed no difference in survival rate,[@ref1] the higher survival rate of patients undergoing PPPD in this study may be attributed to selection bias. Second, we did not investigate the influence of pancreatic cancer-related DM on the survival, mortality and morbidity due to unavailable data. Third, glucose levels are influenced by various factors. Long-term glucose data are needed to clearly demonstrate the effects of DM and the two procedures. However, in the absence of long-term glucose data, the effects might be underestimated. Fourth, long-term data such as dumping syndrome, nutrition status, and marginal ulcer reflecting possible complications are needed. The limitations may be due to difficulties in data collection. Fifth, because the surgical method was not randomly selected, surgical preferences and extent of cancer may have contributed to selection biases. Nevertheless, we believe that our large data provide a comparative and meaningful analysis of the overall differences underlying pylorus preservation and resection in patients with pancreatic head cancer.

In conclusion, PPPD and PRPD showed no significant differences in outcomes compared with conventional interventions reported in previous studies. Although further well-designed studies are needed, it is more important to select the surgical resection range of the patient's disease than the effect of pylorus resection on the patient\'s short- or long-term outcomes.
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![Overall survival of pylorus-preserving and pylorus-resecting pancreaticoduodenectomy. The 5-year survival rates were 27.6% and 22.4% in pylorus-preserving and pylorus-resecting pancreaticoduodenectomy, respectively (*p*=0.015).](AHBPS-24-269-f1){#F1}

![Disease-free survival (DFS) of pylorus-preserving and pylorus-resecting pancreaticoduodenectomy. The 5-year DFS rates were 16.6% and 20.4% in pylorus-preserving and pylorus-resecting pancreaticoduodenectomy, respectively (*p*=0.952).](AHBPS-24-269-f2){#F2}

###### 

Clinical characteristicsof patients undergoing pancreaticoduodenectomy

  Variables                                  Total (n=556)             Pylorus-preserving surgery (n=318)   Pylorus-resecting surgery (n=238)   *p*
  ------------------------------------------ ------------------------- ------------------------------------ ----------------------------------- -----------------------------------------
  Age (years), mean (range)                  62.56 (31-88)             62.11 (35-88)                        63.17 (31-88)                       0.177
  Sex                                                                                                                                           0.003[\*](#t1f2){ref-type="table-fn"}
  Male, n (%)                                334 (60.1)                174 (54.7)                           160 (67.2)                          
  Female, n (%)                              222 (39.9)                144 (45.3)                           78 (32.8)                           
  BMI (kg/m^2^), mean (range)                22.72 (14.43-39.70)       22.80 (14.43-37.57)                  22.61 (15.42-39.70)                 0.385
  Underlying disease                                                                                                                            
  Cardiology, n (%)                          238 (42.8)                127 (39.9)                           111 (46.6)                          0.114
  DM, n (%)                                  215 (38.7)                105 (33.0)                           110 (46.2)                          0.002[\*](#t1f2){ref-type="table-fn"}
  Pulmonary, n (%)                           53 (9.5)                  33 (10.4)                            20 (8.4)                            0.433
  Liver, n (%)                               21 (3.8)                  13 (4.1)                             8 (3.4)                             0.657
  Brain, n (%)                               24 (4.3)                  10 (3.1)                             14 (5.9)                            0.116
  CKD, n (%)                                 6 (1.1)                   2 (0.6)                              4 (1.7)                             0.410
  CEA (ng/ml), median (range)                2.87 (0.20-45.16)         1.91 (0.45-18.99)                    3.17 (0.20-45.16)                   0.351
  CA19-9 (U/ml), median (range)              107.95 (1.00-117557.63)   86.47 (1.00-117557.63)               129.36 (1.00-22999.47)              0.037[\*](#t1f2){ref-type="table-fn"}
  ASA score, n (%)                                                                                                                              0.306
  1                                          102 (18.3)                59 (18.6)                            43 (18.1)                           
  2                                          396 (71.2)                232 (73.0)                           164 (68.9)                          
  3                                          57 (10.3)                 26 (8.2)                             31 (13.0)                           
  4                                          1 (0.2)                   1 (0.3)                              0 (0)                               
  Intraop transfusion, n (%)                 67 (12.1)                 30 (9.4)                             37 (15.5)                           0.028[\*](#t1f2){ref-type="table-fn"}
  EBL (ml), mean (range)                     527.03 (50-5000)          483.11 (100-2650)                    585.71 (50-5000)                    0.104
  Op duration (min), mean (range)            357.32 (138-748)          353.13 (138-620)                     362.93 (145-748)                    0.219
  PV resection, n (%)                        146 (26.3)                74 (23.3)                            72 (30.3)                           0.064
  Soft pancreas, n (%)                       110 (19.8)                82 (25.8)                            28 (11.8)                           \<0.001[\*](#t1f2){ref-type="table-fn"}
  P-duct size, n (%)                         4.2 (0.5-25.0)            4.2 (1.0-25.0)                       4.2 (0.5-19.0)                      0.590
  Postop initial BST (mg/dL), mean (range)   193.9 (49-370)            189.3 (49-370)                       200 (51-365)                        0.004[\*](#t1f2){ref-type="table-fn"}
  Postop mean BST (mg/dL), mean (range)      182.22 (111.17-271.70)    180.12 (111.17-271.70)               185.15 (128.27-266.58)              0.043[\*](#t1f2){ref-type="table-fn"}
  Neoadjuvant Tx, n (%)                      23 (4.1)                  8 (2.5)                              15 (6.3)                            0.027[\*](#t1f2){ref-type="table-fn"}
  Adjuvant Tx, n (%)                         339 (62.9)                197 (64.0)                           142 (61.5)                          0.554

BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; ASA, American Society of Anesthesiologists; Intraop, intraoperative; EBL, estimated blood loss; Op, operative; PV, portal vein; P-duct, pancreatic duct; Postop, postoperative; BST, blood sugar test; Tx, treatment

^\*^indicates statistically significant values

###### 

Pathological characteristics

  Variables                                            Total (n=556)   Pylorus-preserving surgery (n=318)   Pylrus-resecting surgery (n=238)   *p*
  ---------------------------------------------------- --------------- ------------------------------------ ---------------------------------- -------
  T Stage, n (%)                                                                                                                               0.316
  1                                                    105 (18.9)      67 (21.1)                            38 (16.0)                          
  2                                                    386 (69.4)      219 (68.9)                           167 (70.2)                         
  3                                                    55 (9.9)        27 (8.5)                             28 (11.8)                          
  4                                                    9 (1.6)         4 (1.3)                              5 (2.1)                            
  N stage, n (%)                                                                                                                               0.366
  0                                                    169 (30.5)      104 (32.8)                           65 (27.3)                          
  1                                                    246 (44.3)      137 (43.2)                           109 (45.8)                         
  2                                                    140 (25.2)      76 (24.0)                            64 (26.9)                          
  Poorly differentiated, n (%)                         149 (26.8)      79 (24.8)                            70 (29.4)                          0.229
  Harvest LN, n (%)                                    23.7 (3-113)    23.5 (3-113)                         24.1 (4-71)                        0.206
  Positive LN, n (%)                                   2.6 (0-31)      2.4 (0-24)                           3.0 (0-31)                         0.212
  Perineural invasion, n (%)                           486 (94.6)      278 (93.6)                           208 (95.9)                         0.267
  Lymphovascular invasion, n (%)                       278 (79.7)      152 (80.0)                           126 (79.2)                         0.862
  R status, n (%)                                                                                                                              0.033
  R0                                                   373 (67.1)      225 (70.8)                           148 (62.2)                         
  R1 (including rR1[\*](#t1f2){ref-type="table-fn"})   183 (32.9)      93 (29.2)                            90 (37.8)                          
  PV invasion, n (%)                                   113 (20.6)      63 (20.0)                            50 (21.4)                          0.695

LN, lymph node; rR1, revised R1; PV, portal vein

^\*^Revised R1 was defined as a distance of the tumor from the resection margin of ≤1 mm

###### 

Postoperative outcomes

  Variables                                                        Total (n=556)   Pylorus preserving surgery (n=318)   Pylorus-resecting surgery (n=238)   *p*
  ---------------------------------------------------------------- --------------- ------------------------------------ ----------------------------------- -------
  Hospital stay (days), mean (range)                               13.71 (7-80)    14.22 (7-80)                         13.04 (8-42)                        0.692
  Major complications[†](#t3f3){ref-type="table-fn"}, n (%)        97 (17.4)       65 (20.4)                            32 (13.4)                           0.032
  Clinically relevant POPF[‡](#t3f4){ref-type="table-fn"}, n (%)   41 (7.4)        24 (7.5)                             17 (7.1)                            0.857
  DGE, n (%)                                                       40 (7.2)        21 (6.6)                             19 (8.0)                            0.533
  Re-admission[\*](#t3f2){ref-type="table-fn"}, n (%)              63 (11.3)       30 (9.4)                             33 (13.9)                           0.103
  Re-operation[\*](#t3f2){ref-type="table-fn"}, n (%)              17 (3.1)        8 (2.5)                              9 (3.8)                             0.391
  Mortality[\*](#t3f2){ref-type="table-fn"}, n (%)                 41 (7.4)        24 (7.5)                             17 (7.1)                            0.857
  Recurrence, n (%)                                                379 (70.7)      225 (73.8)                           154 (66.7)                          0.074

POPF, postoperative pancreatic fistula; DGE, delayed gastric emptying

^\*^within 90 days

^†^Major complications were defined as Clavien-Dindo Grade III or higher

^‡^Clinically relevant POPF was defined as ≥Grade B of international study group for pancreatic fistula definition

###### 

Major complications

  Variables                               Total (n=97)   Pylorus-preserving surgery (n=65)   Pylorus-resecting surgery (n=32)
  --------------------------------------- -------------- ----------------------------------- ----------------------------------
  Surgical wound problem, n               32             21                                  11
  Intra-abdominal fluid collection, n     27             19                                  8
  Arterial pseudoaneurysm, n              17             9                                   8
  Postoperative bleeding, n               3              3                                   0
  Postoperative sepsis, n                 4              4                                   0
  SMV/PV stenosis or thromboembolism, n   2              2                                   0
  Gastric jejunal ulceration, n           4              3                                   1
  Intestinal obstruction or stenosis, n   6              4                                   2
  Bowel perforation, n                    2              0                                   2

SMV/PV, superior mesenteric vein/portal vein

###### 

Univariate and multivariate analysis of risk factors for major complications

  Variables                                         Univariate   Multivariate                                                                  
  ------------------------------------------------- ------------ -------------- --------------------------------------- ------- -------------- ---------------------------------------
  Age                                               0.423        0.987-1.031    0.423                                                          
  Male                                              1.285        0.814-2.030    0.280                                                          
  BMI                                               1.051        0.982-1.126    0.151                                                          
  Cardiology                                        1.458        0.940-2.263    0.091[\*](#t5f2){ref-type="table-fn"}   1.283   0.802-2.052    0.299
  DM                                                0.974        0.620-1.528    0.907                                                          
  Pulmonary disease                                 1.112        0.538-2.298    0.774                                                          
  Liver disease                                     3.810        1.558-9.314    0.005[\*](#t5f2){ref-type="table-fn"}   3.628   1.451-9.071    0.006[\*](#t5f2){ref-type="table-fn"}
  Brain disease                                     0.418        0.097-1.809    0.406                                                          
  CKD                                               4.851        0.964-24.406   0.069[\*](#t5f2){ref-type="table-fn"}   3.285   0.601-17.949   0.170
  Neoadjuvant Tx                                    0.701        0.204-2.406    0.781                                                          
  PV resection                                      1.102        0.675-1.800    0.698                                                          
  ASA≥3                                             2.623        1.441-4.776    0.001[\*](#t5f2){ref-type="table-fn"}   2.749   1.477-5.114    0.001[\*](#t5f2){ref-type="table-fn"}
  Intraop transfusion                               1.292        0.685-2.437    0.428                                                          
  Total IV input                                    1.000        1.000-1.000    0.278                                                          
  EBL                                               1.000        1.000-1.001    0.146                                                          
  Op duration                                       1.003        1.000-1.005    0.407                                                          
  Soft pancreas                                     0.985        0.568-1.710    0.957                                                          
  P-duct size                                       1.020        0.943-1.103    0.622                                                          
  R1 resection                                      1.062        0.668-1.688    0.798                                                          
  Pylorus resection                                 0.605        0.381-0.959    0.032[\*](#t5f2){ref-type="table-fn"}   0.564   0.351-0.906    0.018[\*](#t5f2){ref-type="table-fn"}
  Postop initial BST                                1.000        0.996-1.005    0.952                                                          
  Postop mean BST                                   0.999        0.991-1.006    0.723                                                          
  Poor BST control[†](#t5f3){ref-type="table-fn"}   1.038        0.670-1.611    0.864                                                          

OR, odds ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; CKD, chronic kidney disease; ASA, American Society of Anesthesiologists; Intraop, intraoperative; IV, intravenous; EBL, estimated blood loss; Op, operative; P-duct, pancreatic duct; Postop, postoperative; BST, blood sugar test

^\*^indicates statistically significant values

^†^Poor BST control was defined as mean BST \>180 mg/dL
